Story perspectives

Abu Dhabi Signs MoUs with Boehringer, Novartis, Arbor

6/27/2026

Summary

Story summary

UAE Health – Abu Dhabi signed MoUs with Boehringer Ingelheim, Novartis and Arbor Biotechnologies at BIO 2026 in San Diego.
The Boehringer Ingelheim and Arbor Biotechnologies agreements will use Abu Dhabi’s genomics and biobank platforms to study precision-medicine for cardiovascular, diabetes, cancer and inherited diseases.
The Novartis MoU will pair the Emirati Genome Program’s 900,000 genomes with Novartis expertise, supported by ADIO’s Health, Endurance, Longevity and Medicine (HELM) Cluster.

1 of 1

Story summary

UAE Health – Abu Dhabi signed MoUs with Boehringer Ingelheim, Novartis and Arbor Biotechnologies at BIO 2026 in San Diego.
The Boehringer Ingelheim and Arbor Biotechnologies agreements will use Abu Dhabi’s genomics and biobank platforms to study precision-medicine for cardiovascular, diabetes, cancer and inherited diseases.
The Novartis MoU will pair the Emirati Genome Program’s 900,000 genomes with Novartis expertise, supported by ADIO’s Health, Endurance, Longevity and Medicine (HELM) Cluster.